Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.66 |
| ▸ | GLUL | P15104 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | OTC | P00480 | 1/20 | 0.56 |
| ▸ | GSR | P00390 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.53 |
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL158652 | 1.00 | BHMT (0.66) | BHMTGLULALDH1A1TDP1OTC | |
| SCHEMBL158653 | 1.00 | BHMT (0.66) | BHMTGLULALDH1A1TDP1OTC | |
| SCHEMBL1978027 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL12648651 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL13997086 | 0.94 | BHMT (0.69) | BHMTGLULTDP1OTCGSR | |
| Water SCHEMBL21747431 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| Hydrochloric Acid SCHEMBL21747394 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL21747440 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| SCHEMBL21747426 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR | |
| Water SCHEMBL21747391 | 0.92 | BHMT (0.67) | BHMTGLULTDP1OTCGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695412-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3551182-B1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHENYTOIN AND A (CO -)AN ALGESIC FOR THE TREATMENT OF CHRONIC PAIN | TOPICAL INNOVATIONS B V (NL) | 2025-03-19 | — | — | EP | disclosed |
| US-20240344041-A1 | ARTIFICIAL PROTEIN TO RESTORE SYNAPTIC FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-10-17 | — | — | US | disclosed |
| WO-2024216030-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPITAL | 2024-05-16 | — | — | US | disclosed |
| EP-3716957-B1 | STEROIDAL COMPOUNDS FOR TREATMENT OF MENTAL AND NEUROLOGICAL DISORDERS | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2023-07-19 | — | — | EP | disclosed |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | RHODE ISLAND HOSPITAL (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-11 | — | — | US | disclosed |
| US-20220193096-A1 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-06-23 | — | — | US | disclosed |
| EP-1861104-A2 | IMPROVED GACYCLIDINE FORMULATIONS | Neurosystec Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1861161-A2 | APPARATUS AND METHOD FOR DELIVERING THERAPEUTIC AND/OR OTHER AGENTS TO THE INNER EAR AND TO OTHER TISSUES | Neurosystec Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060264897-A1 | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues | NEUROSYSTEC CORPORATION (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060205789-A1 | Gacyclidine formulations | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| WO-2006096518-A2 | IMPROVED GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006079055-A2 | APPARATUS AND METHOD FOR DELIVERING THERAPEUTIC AND/OR OTHER AGENTS TO THE INNER EAR AND TO OTHER TISSUES | NEUROSYSTEC CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
| CN-1672055-A | Heterologous stimulus-gated ion channels and methods of using same | SLOAN KETTERING INST CANCER (US) | 2005-09-21 | — | — | CN | disclosed |
| US-6616846-B2 | Extraction of phosphonates | MDS (CANADA) INC. (CA) | 2003-09-09 | — | — | US | disclosed |
| US-20030042204-A1 | Extraction of phosphonates | MDS (CANADA) INC. (CA) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | BHMT 3914/4885GLUL 3952/4885ALDH1A1 2015/4885 |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | NFATC1, TRAF6, UACA | BHMT 3944/4885GLUL 3804/4885ALDH1A1 3763/4885 |
| US-20230142111-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS | GRIN2D, GRIN2A, GRIN2C | BHMT 350/4885GLUL 657/4885ALDH1A1 1764/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | BHMT 3847/4885GLUL 1997/4885ALDH1A1 2097/4885 |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | BHMT 3944/4885GLUL 3804/4885ALDH1A1 3763/4885 |
| US-20060205789-A1 | Gacyclidine formulations | DCTD, TYMP, TYMS | BHMT 1433/4885GLUL 170/4885ALDH1A1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.